L01*Age subgroup analysis of efficacy and safety data from...

Annals of Oncology 2015 / 10 Vol. 26; Iss. suppl 6

L01*Age subgroup analysis of efficacy and safety data from two phase 3 studies of second-line ramucirumab (RAM) versus placebo (PL) in patients (pts) with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINBOW and REGARD):

Cascinu, S., Aprile, G., Pastorelli, D., Pinto, C., Bordonaro, R., Farina, G., Amoroso, D., Bilancia, D., Ciuffreda, L., Sartori, D., Falcone, A., Silvestris, N., Beretta, G.D., Buonadonna, A., Sobrer
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv344.01
Date:
October, 2015
File:
PDF, 42 KB
english, 2015
Conversion to is in progress
Conversion to is failed